AlzeCure publishes its interim report for January - September 2020

AlzeCure publishes its interim report for January - September 2020

PR Newswire

STOCKHOLM, Nov. 17, 2020

STOCKHOLM, Nov. 17, 2020 /PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - September 2020 is now available on the company's website:

"AlzeCure has had another productive quarter during which its operations progressed according to plan, with advances in all three of our project platforms: NeuroRestore, Alzstatin and Painless. Preparations to begin two additional clinical trials at the end of the year for the drug candidates ACD856 and ACD440 are proceeding according to plan."

Martin Jönsson, CEO

Financial information for July - September, 2020

Figures in parentheses refer to the corresponding period of the previous year.

Financial information for January - September, 2020

Figures in parentheses refer to the corresponding period of the previous year

Significant events during the period January - June, 2020

Significant events during the period July - September, 2020

Significant events after the end of the period

Read the full report at:

The information was submitted for publication, through the agency of the contact person set out below at 08.00 am CET on November 17, 2020. 

For more information, please contact

Martin Jönsson, CEO
Tel: +46 (0)70-786 94 43

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of three symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. Alzstatin comprises two disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a clinical candidate for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 , is the company's Certified Adviser. For more information, please visit

This information was brought to you by Cision,c3237686

The following files are available for download:


Martin Jönsson, VD


Voltar noticias em Inglês